Peter J Neumann

Summary

Affiliation: Tufts Medical Center
Country: USA

Publications

  1. ncbi request reprint A strategic plan for integrating cost-effectiveness analysis into the US healthcare system
    Peter J Neumann
    Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, 800 Washington St, 063, Boston, MA 02111, USA
    Am J Manag Care 14:185-8. 2008
  2. doi request reprint Willingness-to-pay for predictive tests with no immediate treatment implications: a survey of US residents
    Peter J Neumann
    Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA
    Health Econ 21:238-51. 2012
  3. doi request reprint FDA actions against health economic promotions, 2002-2011
    Peter J Neumann
    Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts 02111, USA
    Value Health 15:948-53. 2012
  4. doi request reprint Therapies for advanced cancers pose a special challenge for health technology assessment organizations in many countries
    Peter J Neumann
    Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts, USA
    Health Aff (Millwood) 31:700-8. 2012
  5. doi request reprint Risk-sharing arrangements that link payment for drugs to health outcomes are proving hard to implement
    Peter J Neumann
    Center for Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA
    Health Aff (Millwood) 30:2329-37. 2011
  6. ncbi request reprint Low-value services in value-based insurance design
    Peter J Neumann
    Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, MA 02111, USA
    Am J Manag Care 16:280-6. 2010
  7. doi request reprint Costing and perspective in published cost-effectiveness analysis
    Peter J Neumann
    Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, Massachusetts 02111, USA
    Med Care 47:S28-32. 2009
  8. doi request reprint Cancer therapy costs influence treatment: a national survey of oncologists
    Peter J Neumann
    Center for the Evaluationof Value and Risk in Health, Institute for Clinical Researchand Health Policy Studies, Tufts Medical Center, Boston, Massachusetts, USA
    Health Aff (Millwood) 29:196-202. 2010
  9. doi request reprint Is the United States ready for QALYs?
    Peter J Neumann
    Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts, USA
    Health Aff (Millwood) 28:1366-71. 2009
  10. pmc Measuring the value of public health systems: the disconnect between health economists and public health practitioners
    Peter J Neumann
    Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA 02111, USA
    Am J Public Health 98:2173-80. 2008

Detail Information

Publications90

  1. ncbi request reprint A strategic plan for integrating cost-effectiveness analysis into the US healthcare system
    Peter J Neumann
    Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, 800 Washington St, 063, Boston, MA 02111, USA
    Am J Manag Care 14:185-8. 2008
    ..Panelists emphasized the importance of the Medicare program taking a lead role, and the need for new "infrastructure," in the form of either a new institute for conducting research or increased funding for existing institutions...
  2. doi request reprint Willingness-to-pay for predictive tests with no immediate treatment implications: a survey of US residents
    Peter J Neumann
    Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA
    Health Econ 21:238-51. 2012
    ....
  3. doi request reprint FDA actions against health economic promotions, 2002-2011
    Peter J Neumann
    Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts 02111, USA
    Value Health 15:948-53. 2012
    ....
  4. doi request reprint Therapies for advanced cancers pose a special challenge for health technology assessment organizations in many countries
    Peter J Neumann
    Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts, USA
    Health Aff (Millwood) 31:700-8. 2012
    ..Worldwide, we demonstrate that health technology assessment organizations are struggling with cancer's "exceptionalism."..
  5. doi request reprint Risk-sharing arrangements that link payment for drugs to health outcomes are proving hard to implement
    Peter J Neumann
    Center for Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA
    Health Aff (Millwood) 30:2329-37. 2011
    ..For the foreseeable future, they are likely to remain the exception as drug companies pursue payment models unconnected to data collection or performance assessment...
  6. ncbi request reprint Low-value services in value-based insurance design
    Peter J Neumann
    Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, MA 02111, USA
    Am J Manag Care 16:280-6. 2010
    ..To identify potentially low-value services for inclusion in value-based insurance design (VBID) programs and to discuss challenges involved in incorporating such information...
  7. doi request reprint Costing and perspective in published cost-effectiveness analysis
    Peter J Neumann
    Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, Massachusetts 02111, USA
    Med Care 47:S28-32. 2009
    ..Questions linger about what cost components to include under a "societal" perspective, as well as how to value resources...
  8. doi request reprint Cancer therapy costs influence treatment: a national survey of oncologists
    Peter J Neumann
    Center for the Evaluationof Value and Risk in Health, Institute for Clinical Researchand Health Policy Studies, Tufts Medical Center, Boston, Massachusetts, USA
    Health Aff (Millwood) 29:196-202. 2010
    ..The results also support educating physicians about cost-effectiveness and how to communicate with patients regarding cost...
  9. doi request reprint Is the United States ready for QALYs?
    Peter J Neumann
    Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts, USA
    Health Aff (Millwood) 28:1366-71. 2009
    ..S. health care system. Strict adherence to a QALY approach is likely to prove unacceptable in the United States, but a more flexible use of QALYs could be beneficial...
  10. pmc Measuring the value of public health systems: the disconnect between health economists and public health practitioners
    Peter J Neumann
    Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA 02111, USA
    Am J Public Health 98:2173-80. 2008
    ..g., social justice and reassurance value). Academic researchers evaluating the economics of public health investments should increase focus on the working needs of public health professionals...
  11. doi request reprint Medicare's national coverage decisions for technologies, 1999-2007
    Peter J Neumann
    Institute for Clinical Research and Health Policy Studies, at Tufts Medical Center in Boston, Massachusetts, USA
    Health Aff (Millwood) 27:1620-31. 2008
    ....
  12. ncbi request reprint Do drug formulary policies reflect evidence of value?
    Peter J Neumann
    Department of Health Policy and Management and Center for Risk Analysis, Harvard School of Public Health, Boston, MA 02115, USA
    Am J Manag Care 12:30-6. 2006
    ..To investigate the extent to which preferred drug lists and tiered formularies reflect evidence of value, as measured in published cost-utility analyses (CUAs)...
  13. ncbi request reprint Growth and quality of the cost-utility literature, 1976-2001
    Peter J Neumann
    Program on the Economic Evaluation of Medical Technology, Center for Risk Analysis, Harvard School of Public Health, Boston, MA 02115, USA
    Value Health 8:3-9. 2005
    ..This study updates and expands our previous work, which examined CUAs through 1997...
  14. ncbi request reprint Do oncologists believe new cancer drugs offer good value?
    Eric Nadler
    Dana Faber Cancer Institute Harvard Medical School, Boston, MA, USA
    Oncologist 11:90-5. 2006
    ..Oncologists play a pivotal role in treatment decisions, yet it is unclear whether they perceive high-cost new treatments to offer good value or how therapeutic costs factor into their treatment recommendations...
  15. ncbi request reprint Can we better prioritize resources for cost-utility research?
    Peter J Neumann
    Harvard School of Public Health, Boston, MA 02115, USA
    Med Decis Making 25:429-36. 2005
    ....
  16. ncbi request reprint Trends in the measurement of health utilities in published cost-utility analyses
    Carmen A Brauer
    Harvard Center for Risk Analysis, Harvard School of Public Health, Boston, MA, USA
    Value Health 9:213-8. 2006
    ..tufts-nemc.org/cearegistry; previously at http://www.hsph.harvard.edu/cearegistry), and documents recent changes in methods used for utility weight elicitation...
  17. ncbi request reprint Quality of clinical and economic evidence in dossier formulary submissions
    Fernando Colmenero
    Harvard School of Public Health, Boston, MA, USA
    Am J Manag Care 13:401-7. 2007
    ..To investigate the quality and completeness of clinical and economic data in dossiers submitted by drug companies to a health plan using Academy of Managed Care Pharmacy guidelines (the Format) for formulary submissions...
  18. doi request reprint The adoption of cost-effectiveness acceptability curves in cost-utility analyses
    Lisa M Meckley
    Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts 02111, USA
    Med Decis Making 30:314-9. 2010
    ..g., life-years or quality-adjusted life-years gained)...
  19. ncbi request reprint Medicare and cost-effectiveness analysis
    Peter J Neumann
    Department of Health Policy and Management and the Center for Risk Analysis, Harvard School of Public Health, Boston, USA
    N Engl J Med 353:1516-22. 2005
  20. pmc Cost-effective diagnostic cardiovascular imaging: when does it provide good value for the money?
    Hansel J Otero
    Department of Radiology, Tufts Medical Center and Tufts University School of Medicine, Boston, MA 02111, USA
    Int J Cardiovasc Imaging 26:605-12. 2010
    ..The studies available have, in general, favorable cost-effectiveness profiles with major determinants relating to being compared against observation, medical or no intervention instead of other imaging tests...
  21. doi request reprint 30 years of pharmaceutical cost-utility analyses: growth, diversity and methodological improvement
    Peter J Neumann
    The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts, USA
    Pharmacoeconomics 27:861-72. 2009
    ..The results highlight that there are many opportunities for efficient healthcare investment, among pharmaceutical and non-pharmaceutical interventions, just as there are many investments that are inefficient...
  22. doi request reprint A bibliometric review of cost-effectiveness analyses in the economic and medical literature: 1976-2006
    Dan Greenberg
    Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts, USA
    Med Decis Making 30:320-7. 2010
    ..Despite the proliferation of CEA research, there has been no detailed study focusing on the bibliometric properties of this literature...
  23. doi request reprint What can we learn from the U.S. expanded end-stage renal disease bundle?
    James D Chambers
    The Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA 02111, USA
    Health Policy 110:164-71. 2013
    ..Bundled payment policies offer opportunities and challenges. Their success will be determined not only by impacts on cost containment, but also to the extent they encourage high quality care...
  24. doi request reprint Willingness to pay for diagnostic technologies: a review of the contingent valuation literature
    Pei Jung Lin
    Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA 02111, USA
    Value Health 16:797-805. 2013
    ..To understand how people value information from diagnostic technologies, we reviewed and analyzed published willingness-to-pay (WTP) studies on the topic...
  25. doi request reprint Medicare's national coverage determinations in diagnostic radiology: examining evidence and setting limits
    Hansel Javier Otero
    Department of Radiology, Institute for Clinical Research and Health Policy Studies, Boston, MA 02111, USA
    Acad Radiol 19:1060-5. 2012
    ..To systematically review and summarize the Center for Medicare and Medicaid Services (CMS) national coverage determination (NCDs) pertaining diagnostic imaging technologies from 1999 through 2010...
  26. ncbi request reprint The arrival of economic evidence in managed care formulary decisions: the unsolicited request process
    Peter J Neumann
    Department of Policy and Decision Sciences, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Med Care 43:27-32. 2005
    ..This article describes the unsolicited request process and its potential impact on the use of economic evidence in formulary decisions...
  27. doi request reprint Does adjusting for health-related quality of life matter in economic evaluations of cancer-related interventions?
    Dan Greenberg
    The Center for the Evaluation of Value and Risk in Health, The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA
    Expert Rev Pharmacoecon Outcomes Res 11:113-9. 2011
    ..We investigated the extent to which adjusting for health-related quality of life (HRQoL) alters incremental cost per life-year gained ratios, and the implications for reimbursement decisions...
  28. ncbi request reprint Challenges ahead for federal technology assessment
    Peter J Neumann
    Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts New England Medical Center, MA, USA
    Health Aff (Millwood) 26:w150-2. 2007
    ..Efforts are also needed to prioritize research, to communicate it to decision-makers, to involve stakeholders in the process, and to include cost-effectiveness information...
  29. doi request reprint Early trends from the Study to Evaluate the Prospective Payment System Impact on Small Dialysis Organizations (STEPPS)
    Steven M Brunelli
    Renal Division and Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
    Am J Kidney Dis 61:947-56. 2013
    ..This report details early results between October 2010 and June 2011...
  30. doi request reprint Does framing of cancer survival affect perceived value of care? A willingness-to-pay survey of US residents
    Pei Jung Lin
    Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA
    Expert Rev Pharmacoecon Outcomes Res 13:513-22. 2013
    ..To investigate the relationship between the framing of survival gains and the perceived value of cancer care...
  31. doi request reprint A role for research: an observation on preventive services for women
    Natalia Olchanski
    Center for Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts 02111, USA
    Am J Prev Med 44:S12-5. 2013
    ..The Patient Protection and Affordable Care Act of 2010 (ACA) added preventive services for women, recommended by the IOM, to healthcare coverage requirements beginning in August 2011...
  32. doi request reprint US FDA Modernization Act, section 114: uses, opportunities and implications for comparative effectiveness research
    Peter J Neumann
    Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts, USA
    Pharmacoeconomics 29:687-92. 2011
    ....
  33. ncbi request reprint Drug company advertising in medical journals about the health-economic advantages of their products for 2000-2006 versus 1990-1999
    Jennifer A Palmer
    Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, 800 Washington Street, 063, Boston, MA 02111, USA jpalmer tuftsmedicalcenter org
    J Manag Care Pharm 14:749-55. 2008
    ..We previously investigated the promotional claims made by pharmaceutical companies about the economic advantages of their prescription products in print advertisements in 6 leading medical journals from 1990-1999...
  34. doi request reprint A framework for assessing the value of diagnostic imaging in the era of comparative effectiveness research
    G Scott Gazelle
    Department of Radiology, Institute for Technology Assessment, Massachusetts General Hospital, 101 Merrimac St, 10th Floor, Boston, MA 02114 4724, USA
    Radiology 261:692-8. 2011
    ....
  35. doi request reprint Potentially avoidable hospitalizations among Medicare beneficiaries with Alzheimer's disease and related disorders
    Pei Jung Lin
    Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA
    Alzheimers Dement 9:30-8. 2013
    ..Individuals with Alzheimer's disease and related disorders (ADRD) have more frequent hospitalizations than individuals without ADRD, and some of these admissions may be preventable with proactive outpatient care...
  36. doi request reprint Medicare's enduring struggle to define "reasonable and necessary" care
    Peter J Neumann
    Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, USA
    N Engl J Med 367:1775-7. 2012
    ..In today's fiscal environment, "reasonable and necessary" warrants a closer look...
  37. ncbi request reprint Does preventive care save money? Health economics and the presidential candidates
    Joshua T Cohen
    Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts New England Medical Center, Boston, USA
    N Engl J Med 358:661-3. 2008
  38. ncbi request reprint When does quality-adjusting life-years matter in cost-effectiveness analysis?
    Richard H Chapman
    Program on the Economic Evaluation of Medical Technology, Harvard Center for Risk Analysis, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Health Econ 13:429-36. 2004
    ....
  39. doi request reprint A review of the costs and cost effectiveness of interventions in chronic kidney disease: implications for policy
    Joseph Menzin
    Boston Health Economics, Inc, Waltham, MA, USA
    Pharmacoeconomics 29:839-61. 2011
    ..In order to realize these cost savings, efforts will be required to promote and effectively implement changes in treatment practices...
  40. doi request reprint Cost-utility analyses of diagnostic laboratory tests: a systematic review
    Chihui Fang
    Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA 02111, USA
    Value Health 14:1010-8. 2011
    ..To review and evaluate the literature of cost-utility analyses (CUAs) regarding diagnostic laboratory testing...
  41. ncbi request reprint Economic evaluation in the US: what is the missing link?
    Peter J Neumann
    Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Care Policy, Tufts New England Medical Center, Boston, Massachusetts, USA
    Pharmacoeconomics 24:1163-8. 2006
    ..However, a more likely outcome is the ongoing indirect use of cost-effectiveness information...
  42. ncbi request reprint Medicare's national coverage decisions, 1999-2003: quality of evidence and review times
    Peter J Neumann
    Harvard School of Public Health in Boston, Massachusetts, USA
    Health Aff (Millwood) 24:243-54. 2005
    ..Decisions referred to the external Medicare Coverage Advisory Committee (MCAC) have averaged eight months longer than non-MCAC decisions...
  43. doi request reprint Decision analytic models for Alzheimer's disease: state of the art and future directions
    Joshua T Cohen
    Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts New England Medical Center, Boston, MA, USA
    Alzheimers Dement 4:212-22. 2008
    ....
  44. ncbi request reprint Cost-utility analyses in orthopaedic surgery
    Carmen A Brauer
    Harvard Center for Risk Analysis, Harvard School of Public Health, 718 Huntington Avenue, Boston, MA 02115, USA
    J Bone Joint Surg Am 87:1253-9. 2005
    ..We critically reviewed the literature on orthopaedic cost-utility analysis to determine which subspecialty areas are represented, the cost-utility ratios that have been utilized, and the quality of the present literature...
  45. ncbi request reprint When is critical care medicine cost-effective? A systematic review of the cost-effectiveness literature
    Daniel Talmor
    Department of Anesthesia, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    Crit Care Med 34:2738-47. 2006
    ..Cost-effectiveness analyses (CEAs) have become increasingly common to aid decisions about the allocation of scarce healthcare resources...
  46. ncbi request reprint Economic messages in prescription drug advertisements in medical journals
    Peter J Neumann
    Program on the Economic Evaluation of Medical Technology, Center for Risk Analysis Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Med Care 40:840-5. 2002
    ..Our objectives were to examine how often prescription drug advertisements in leading medical journals contain economic messages, and to determine the types of promotional claims made and whether supporting evidence is provided...
  47. doi request reprint Accuracy, risk and the intrinsic value of diagnostic imaging: a review of the cost-utility literature
    Hansel J Otero
    Department of Radiology, Tufts Medical Center, 800 Washington Street, Boston, MA 02111, USA
    Acad Radiol 19:599-606. 2012
    ..The aim of this study was to systematically review the reporting of the value of imaging unrelated to treatment consequences and test characteristics in all imaging-related published cost-utility analyses (CUAs) in the medical literature...
  48. doi request reprint Migraine frequency and health utilities: findings from a multisite survey
    Jeffrey S Brown
    Department of Ambulatory Care and Prevention, Harvard Medical School Harvard Pilgrim Health Care, Boston, MA, USA
    Value Health 11:315-21. 2008
    ..Assess the relationship between migraine frequency and health utility...
  49. ncbi request reprint Cost-effectiveness of PET in the diagnosis of Alzheimer disease
    Pamela M McMahon
    Institute for Technology Assessment, Massachusetts General Hospital, Zero Emerson Place, Suite 2H, Boston, MA 02114, USA
    Radiology 228:515-22. 2003
    ..To evaluate the cost-effectiveness of positron emission tomography (PET) in the diagnosis of Alzheimer disease (AD) in community-dwelling patients with mild or moderate dementia who present to specialized AD centers...
  50. pmc The effect of immediate reading of screening mammograms on medical care utilization and costs after false-positive mammograms
    Kate A Stewart
    Department of Health Care Policy, 180 Longwood Avenue, Boston, MA 02115, USA
    Health Serv Res 42:1464-82. 2007
    ..To investigate whether decreased anxiety associated with immediate reading of screening mammograms resulted in lower downstream utilization and costs among women with false-positive mammograms...
  51. ncbi request reprint Emerging lessons from the drug effectiveness review project
    Peter J Neumann
    Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts New England Medical Center, Boston, Massachusetts, USA
    Health Aff (Millwood) 25:W262-71. 2006
    ....
  52. pmc When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology
    Dan Greenberg
    Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA 02111, USA
    J Natl Cancer Inst 102:82-8. 2010
    ..Because we found only modest improvement in the quality of studies, we suggest that journals provide specific guidance for reporting CUA and assure that authors adhere to guidelines for conducting and reporting economic evaluations...
  53. doi request reprint Does Medicare have an implicit cost-effectiveness threshold?
    James D Chambers
    Health Economics Research Group, Brunel University, Uxbridge, UK
    Med Decis Making 30:E14-27. 2010
    ..Despite the huge cost of the program, the Centers for Medicare and Medicaid Services (CMS) has maintained a policy that cost-effectiveness is not considered in national coverage determinations (NCDs)...
  54. doi request reprint Regression analysis on the variation in efficiency frontiers for prevention stage of HIV/AIDS
    Maki S Kamae
    Division of Medical Statistics, Graduate School of Medicine, Kobe University, Japan
    J Med Econ 14:187-93. 2011
    ....
  55. ncbi request reprint Association between preference-based health-related quality of life and asthma severity
    Marilyn L Moy
    Division of Pulmonary and Critical Care Medicine and Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Ann Allergy Asthma Immunol 92:329-34. 2004
    ..International guidelines have been developed to guide medical management according to asthma severity defined by lung function and symptom frequency...
  56. ncbi request reprint Evidence-based and value-based formulary guidelines
    Peter J Neumann
    Program on the Economic Evaluation of Medical Technology, Center for Risk Analysis, Harvard School of Public Health, Boston, Massachusetts, USA
    Health Aff (Millwood) 23:124-34. 2004
    ..This paper describes the guidelines, reviews progress to date, and analyzes several critical issues for the future...
  57. ncbi request reprint Why don't Americans use cost-effectiveness analysis?
    Peter J Neumann
    Program on the Economic Evaluation of Medical Technology, Center for Risk Analysis, Harvard School of Public Health, Boston, MA 02115, USA
    Am J Manag Care 10:308-12. 2004
    ..This paper examines the resistance to CEA in the United States and explores ways in which to advance the field...
  58. doi request reprint Using decision analysis to better evaluate pediatric clinical guidelines
    Joshua T Cohen
    Tufts Medical Center, Center for the Evaluation of Value and Risk CEVR, Boston, Massachusetts, USA
    Health Aff (Millwood) 27:1467-75. 2008
    ..It is particularly useful for pediatric research, where randomized controlled trials are often unavailable and infeasible. Policymakers should incorporate decision analysis into comparative effectiveness research and clinical guidelines...
  59. ncbi request reprint Quality-adjusted life years: how useful in medico economic studies
    Carmen A Brauer
    Program on the Economic Evaluation of Medical Technology, Harvard Center for Risk Analysis, Harvard School of Public Health, Boston, MA, USA
    Fundam Clin Pharmacol 19:603-7. 2005
    ..The purpose of this paper is to highlight some of the issues surrounding the use of QALYs and to encourage researchers to present their methodology in a clear and transparent way...
  60. pmc Twenty years of cost-effectiveness analysis in medical imaging: are we improving?
    Hansel J Otero
    Department of Radiology, Brigham and Women s Hospital, Harvard Medical School, 75 Francis St, Boston, MA 02115, USA
    Radiology 249:917-25. 2008
    ..S. Panel on Cost-effectiveness in Health and Medicine recommendations affected CEA studies in which imaging technologies were evaluated...
  61. ncbi request reprint Valuing children's health: a comparison of cost-utility analyses for adult and paediatric health interventions in the US
    Joseph A Ladapo
    Harvard Medical School and Harvard Graduate School of Arts and Sciences, Boston, Massachusetts, USA
    Pharmacoeconomics 25:817-28. 2007
    ....
  62. pmc Delays in publication of cost utility analyses conducted alongside clinical trials: registry analysis
    Dan Greenberg
    Harvard Center for Risk Analysis, Department of Health Policy and Management, Harvard School of Public Health, 718 Huntington Avenue, Boston, MA 02115, USA
    BMJ 328:1536-7. 2004
  63. doi request reprint The economics of mild cognitive impairment
    Pei Jung Lin
    Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA
    Alzheimers Dement 9:58-62. 2013
    ..Such analyses should help payers, providers, and policy makers make more informed decisions about the costs and benefits of new tests, treatments, and other management strategies for the condition...
  64. doi request reprint Illustrating potential efficiency gains from using cost-effectiveness evidence to reallocate Medicare expenditures
    James D Chambers
    Health Economics Research Group, Brunel University, Uxbridge, UK
    Value Health 16:629-38. 2013
    ..The objective of this study was to illustrate potential efficiency gains from reallocating Medicare expenditures by using cost-effectiveness information, and the consequences for health gains among Medicare beneficiaries...
  65. ncbi request reprint FDA actions against misleading or unsubstantiated economic and quality-of-life promotional claims: an analysis of warning letters and notices of violation
    Kate A Stewart
    Program on the Economic Evaluation of Medical Technology, Center for Risk Analysis, Harvard School of Public Health, 7218 Huntington Avenue, Boston, MA 02115, USA
    Value Health 5:390-7. 2002
    ..The objective of this study was to understand the types of economic and quality-of-life promotional claims the FDA considers false or misleading...
  66. ncbi request reprint What's more dangerous, your aspirin or your car? Thinking rationally about drug risks (and benefits)
    Joshua T Cohen
    Tufts New England Medical Center, Boston, Massachusetts, USA
    Health Aff (Millwood) 26:636-46. 2007
    ..We discuss the need for the Food and Drug Administration to compare risks and benefits quantitatively, consistently, and explicitly...
  67. ncbi request reprint Direct-to-consumer advertising and shared liability for pharmaceutical manufacturers
    Michelle M Mello
    Department of Health Policy and Management, Harvard School of Public Health, 677 Huntington Ave, Boston, Mass 02115, USA
    JAMA 289:477-81. 2003
  68. ncbi request reprint Do HEDIS measures reflect cost-effective practices?
    Peter J Neumann
    Program on the Economic Evaluation of Medical Technology, Center for Risk Analysis, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Am J Prev Med 23:276-89. 2002
    ..Our study objectives were to examine the cost-effectiveness evidence for the clinical practices underlying HEDIS 2000 measures and to develop a list of practices not reflected in HEDIS that have evidence of cost effectiveness...
  69. ncbi request reprint Health utilities in Alzheimer's disease and implications for cost-effectiveness analysis
    Peter J Neumann
    Department of Health Policy and Management and Center for Risk Analysis, Harvard School of Public Health, Boston, Massachusetts, USA
    Pharmacoeconomics 23:537-41. 2005
    ..The NICE assumption that they do not results in a difference in utilities between dependent and non-dependent AD individuals of only 0.06. This seems to be at the low end of what one would consider a reasonable estimate...
  70. ncbi request reprint Dialysis facility ownership and epoetin dosing in hemodialysis patients: a medical economic perspective
    Joshua T Cohen
    Institute for Clinical Research and Health Policy Studies, Tufts New England Medical Center, Boston, Massachusetts 02111, USA
    Am J Kidney Dis 50:362-5. 2007
  71. ncbi request reprint Willingness to pay for avoiding coronary restenosis and repeat revascularization: results from a contingent valuation study
    Dan Greenberg
    Harvard Clinical Research Institute, Boston, MA, USA
    Health Policy 70:207-16. 2004
    ..The contingent valuation approach may offer particular advantages when evaluating treatments that improve short-term health outcomes...
  72. doi request reprint Personalized medicine: factors influencing reimbursement
    Lisa M Meckley
    Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, 800 Washington St, 63, Boston, MA 02111, USA
    Health Policy 94:91-100. 2010
    ..Personalized medicine (PM) has attracted tremendous interest, but yielded few marketed products. We examined factors influencing the reimbursement of existing PM technologies...
  73. doi request reprint Imputing productivity gains from clinical trials
    Michael J Cangelosi
    Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, MA, USA
    J Occup Environ Med 54:826-33. 2012
    ..To respond to employer and payer interest in the extent to which productivity gains offset therapy costs by identifying clinical trials that did not include such measures and using their clinical data to impute productivity impact...
  74. ncbi request reprint Cross-national comparison of technology assessment processes
    Anna García-Altés
    Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Int J Technol Assess Health Care 20:300-10. 2004
    ..To compare methods and results among four health technology assessment organizations in different countries...
  75. ncbi request reprint When is evidence sufficient?
    Karl Claxton
    University of York, United Kingdom
    Health Aff (Millwood) 24:93-101. 2005
    ..Value-of-information analysis, a related methodology, helps to determine whether it is worthwhile to collect additional information as well as the type of research that would be most helpful...
  76. ncbi request reprint Examining the value and quality of health economic analyses: implications of utilizing the QHES
    Joshua J Ofman
    Zynx Health Inc, 9100 Wilshire Blvd, East Tower, Suite 655, Beverly Hills, CA 90212, USA
    J Manag Care Pharm 9:53-61. 2003
    ..To examine the increasing use of health economic studies and practical implications of evaluating their quality utilizing the Quality of Health Economic Studies (QHES) instrument...
  77. ncbi request reprint Development and validation of a grading system for the quality of cost-effectiveness studies
    Chiun Fang Chiou
    Zynx Health Inc, Cerner Corporation, Beverly Hills, California 90212, USA
    Med Care 41:32-44. 2003
    ..To provide a practical quantitative tool for appraising the quality of cost-effectiveness (CE) studies...
  78. ncbi request reprint The impact of Medicare modernization on coverage policy: recommendations for reform
    Susan Bartlett Foote
    Division of Health Services Research and Policy, School of Public Health, University of Minnesota, Minneapolis, Minn 55455, USA
    Am J Manag Care 11:140-2. 2005
  79. ncbi request reprint Economic burden of pertussis and the impact of immunization
    J Jaime Caro
    Caro Research Institute, Concord, MA 01742, USA
    Pediatr Infect Dis J 24:S48-54. 2005
    ..Despite the existing gaps in data, further research using the most current data should facilitate decisions on new vaccination strategies by describing conditions for favorable results and quantifying the margin of uncertainty...
  80. doi request reprint Key principles for the improved conduct of health technology assessments for resource allocation decisions
    Michael F Drummond
    Centre for Health Economics, University of York, Heslington, York, UK
    Int J Technol Assess Health Care 24:244-58; discussion 362-8. 2008
    ..The principles are organized into four sections: (i) "Structure" of HTA programs; (ii) "Methods" of HTA; (iii) "Processes for Conduct" of HTA; and (iv) "Use of HTAs in Decision Making."..
  81. ncbi request reprint Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report
    Louis P Garrison
    University of Washington, Seattle, WA 98195, USA
    Value Health 10:326-35. 2007
    ....
  82. ncbi request reprint Trends in cost effectiveness analyses in orthopaedic surgery
    Carmen A Brauer
    Department of Orthopaedic Surgery, British Columbia Children s Hospital, Vancouver, BC, Canada
    Clin Orthop Relat Res 457:42-8. 2007
    ....
  83. ncbi request reprint Biotechnology and Medicare's new technology policy: lessons from three case studies
    Patricia Seliger Keenan
    Division of Health Policy and Administration, Department of Epidemiology and Public Health, Yale University School of Medicine in New Haven, Connecticut, USA
    Health Aff (Millwood) 25:1260-9. 2006
    ..The cases suggest Medicare's ongoing challenge to balance access considerations, the role and strength of evidence, and cost consequences of new treatments...
  84. ncbi request reprint What affects the quality of economic analysis for life-saving investments?
    Robert W Hahn
    AEI Brookings Joint Center for Regulatory Studies, Washington, DC 20036, USA
    Risk Anal 26:641-55. 2006
    ..Somewhat surprisingly, a study's funding source and whether it is affiliated with industry are not significantly correlated with the quality index. Finally, neither time nor the panel guidelines had an impact on the index...
  85. pmc Bias in published cost effectiveness studies: systematic review
    Chaim M Bell
    St Michael s Hospital, Toronto, Ontario, Canada M5B 1W8
    BMJ 332:699-703. 2006
    ....
  86. ncbi request reprint Diffusion of published cost-utility analyses in the field of health policy and practice
    Seema S Sonnad
    Department of Surgery, University of Pennsylvania, Philadelphia, Pennsylvania 19104 4283, USA
    Int J Technol Assess Health Care 21:399-402. 2005
    ..The diffusion of cost-utility analyses (CUAs) through the medical literature was examined, documenting visible patterns and determining how they correspond with expectations about the diffusion of process innovations...
  87. ncbi request reprint Cost-effectiveness of topiramate in migraine prevention: results from a pharmacoeconomic model of topiramate treatment
    Jeffrey S Brown
    Boston Health Economics, Inc, Waltham, MA 02451, USA
    Headache 45:1012-22. 2005
    ..This cost-effectiveness model assesses the clinical and economic impact of topiramate (TPM) therapy versus no preventive treatment for migraine headache in the United States...
  88. ncbi request reprint Quality of abstracts of papers reporting original cost-effectiveness analyses
    Allison B Rosen
    Division of General Medicine, University of Michigan Health Systems, Department of Health Management and Policy, University of Michigan School of Public Health, Ann Arbor Veterans Affairs Medical Center, Ann Arbor, MI 48109, USA
    Med Decis Making 25:424-8. 2005
    ..The authors examined the extent to which abstracts of published CEAs include key data elements (intervention, comparator, target population, study perspective) and assessed the effect of journal characteristics on reporting quality...
  89. ncbi request reprint A synthesis of cost-utility analysis literature in infectious disease
    Patricia W Stone
    Columbia University School of Nursing, New York, NY 10032, USA
    Lancet Infect Dis 5:383-91. 2005
    ..The results of cost-utility analyses have important implications for the development of clinical guidelines and resource allocation decisions. More trained investigators and better peer-review processes are needed...
  90. ncbi request reprint Budget impact analyses get some respect
    Peter J Neumann
    Value Health 10:324-5. 2007